Lee Seokkee, Lee Chang Young, Kim Dae Joon, Hong Dae Jin, Lee Jin Gu, Chung Kyung Young
Department of Thoracic and Cardiovascular Surgery, Yonsei University College of Medicine, Korea.
Korean J Thorac Cardiovasc Surg. 2013 Jun;46(3):192-6. doi: 10.5090/kjtcs.2013.46.3.192. Epub 2013 Jun 5.
This study focused on the association between preoperative serum carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (Cyfra 21-1) levels and pathologic parameters in patients with resected non-small-cell lung cancer (NSCLC).
The records of 527 patients who underwent pulmonary resection of NSCLC were reviewed. The association between preoperative serum CEA and Cyfra 21-1 levels and variables that had p-values of less than 0.05 in a t-test or one-way analyses of variance was analyzed by multiple linear regression.
The mean serum CEA and Cyfra 21-1 levels prior to surgery were 6.8±23.1 mg/dL (range, 0.01 to 390.8 mg/dL) and 5.4±12.3 mg/dL (range, 0.65 to 140.2 mg/dL). The serum CEA levels were associated with tumor (T) and lymph node (N) stage and histology. The serum Cyfra 21-1 levels were associated with T stage, tumor size, and histology. Multiple linear regression indicated that serum CEA levels were associated with T (T3/4 vs. T1: β=8.463, p=0.010) and N stage (N2/3 vs. N0: β=9.208, p<0.001) and histology (adenocarcinoma vs. squamous cell: β=6.838, p=0.001), and serum Cyfra 21-1 levels were associated with tumor size (β=2.579, p<0.001) and histology (squamous cell vs. adenocarcinoma: β=4.420, p=0.020).
Serum CEA level was correlated with T and N stage, and Cyfra 21-1 with tumor size. CEA and Cyfra 21-1 showed histologic correlation. CEA is mainly elevated in adenocarcinoma and Cyfra 21-1 in squamous cell carcinoma. These results might be helpful for predicting pathologic status in preoperative NSCLC.
本研究聚焦于接受手术切除的非小细胞肺癌(NSCLC)患者术前血清癌胚抗原(CEA)和细胞角蛋白19片段(Cyfra 21-1)水平与病理参数之间的关联。
回顾了527例行NSCLC肺切除术患者的病历。通过多元线性回归分析术前血清CEA和Cyfra 21-1水平与在t检验或单因素方差分析中p值小于0.05的变量之间的关联。
术前血清CEA和Cyfra 21-1的平均水平分别为6.8±23.1 mg/dL(范围:0.01至390.8 mg/dL)和5.4±12.3 mg/dL(范围:0.65至140.2 mg/dL)。血清CEA水平与肿瘤(T)和淋巴结(N)分期及组织学类型相关。血清Cyfra 21-1水平与T分期、肿瘤大小及组织学类型相关。多元线性回归表明,血清CEA水平与T分期(T3/4期与T1期:β=8.463,p=0.010)、N分期(N2/3期与N0期:β=9.208,p<0.001)及组织学类型(腺癌与鳞癌:β=6.838,p=0.001)相关,血清Cyfra 21-1水平与肿瘤大小(β=2.579,p<0.001)及组织学类型(鳞癌与腺癌:β=4.420,p=0.020)相关。
血清CEA水平与T和N分期相关,Cyfra 21-1与肿瘤大小相关。CEA和Cyfra 21-1显示出组织学相关性。CEA主要在腺癌中升高,Cyfra 21-1在鳞癌中升高。这些结果可能有助于预测术前NSCLC的病理状态。